Blockade of angiotensin II modulates insulin-like growth factor 1-mediated skeletal muscle homeostasis in experimental steatohepatitis.

Autor: Tanaka M; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Kaji K; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan. Electronic address: kajik@naramed-u.ac.jp., Nishimura N; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Asada S; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Koizumi A; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Matsuda T; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Yorioka N; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Tsuji Y; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Fujinaga Y; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Sato S; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Namisaki T; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Akahane T; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan., Yoshiji H; Department of Gastroenterology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Jazyk: angličtina
Zdroj: Biochimica et biophysica acta. Molecular cell research [Biochim Biophys Acta Mol Cell Res] 2024 Feb; Vol. 1871 (2), pp. 119649. Date of Electronic Publication: 2023 Dec 12.
DOI: 10.1016/j.bbamcr.2023.119649
Abstrakt: Sarcopenia is associated with mortality in patients with nonalcoholic steatohepatitis (NASH). Angiotensin II receptor blocker (ARB) has been suggested to prevent sarcopenia, but reports on its effect on NASH-derived skeletal muscle atrophy in conjunction with insulin-like growth factor 1 (IGF-1)-mediated muscle homeostasis are few. Our aim was to examine the combined effect of the ARB losartan and IGF-1 replacement on skeletal muscle atrophy in a methionine-choline deficient (MCD) diet-fed murine steatohepatitis model. The MCD-fed mice developed steatohepatitis and skeletal muscle atrophy, as indicated by the reduction of psoas muscle mass and attenuation of forelimb and hindlimb grip strength. Significantly suppressed steatohepatitis and skeletal muscle atrophy was observed after single treatment with ARB or IGF-1, and these effects were augmented after combination treatment. Treatment with ARB and IGF-1 effectively inhibited ubiquitin proteasome-mediated protein degradation by reducing forkhead box protein O1 (FOXO1) and FOXO3a transcriptional activity in the skeletal muscle. Combined ARB and IGF-1 decreased the intramuscular expression of proinflammatory cytokines (i.e., TNFα, IL6, and IL1β) and increased the Trolox equivalent antioxidant capacity and antioxidant enzymes (CAT, GPX1, SOD2, and CYTB). This antioxidant effect was based on downregulation of NADPH oxidase (NOX) 2, normalization of mitochondrial biogenesis and dynamics. Moreover, ARB increased the hepatic and plasma IGF-1 levels and improved steatohepatitis, leading to enhanced skeletal muscle protein synthesis mediated by IGF-1/ AKT/ mechanistic target of rapamycin signaling. Collectively, combined ARB and IGF-1 replacement could be a promising new therapeutic target for NASH-derived skeletal muscle wasting.
Competing Interests: Declaration of competing interest No potential conflicts of interest were disclosed by all authors.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: